Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Stopped early · Phase 3

Conditions studied: Relapsing Remitting Multiple Sclerosis

In brief

This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg). Participants were to be randomized to receive natalizumab, interferon β-1a 44 μg, or glatiramer acetate.

Key facts

Study ID
NCT01058005
Run by
Biogen
People needed
84
Starts
2010-03-01
Expected to finish
2012-04-01
Last updated by the study team
2014-09-03

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.